Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2019 · 10-Q
Revenue—
Net Income-$863.62K-$863.62KN/M vs Q3 2018 EPS Diluted-$0.01-$0.01N/M vs Q3 2018 Operating Cash Flowderived-$1,751,424N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end